Document is current
Any future updates will be listed below
-
Authors
Le, Thi Thao Truc
Martinent, Guillaume
Dupuis-Girod, Sophie
Parrot, Antoine
Contis, Anne
Riviere, Sophie
Chinet, Thierry
Grobost, Vincent
Espitia, Olivier
Dussardier-Gilbert, Brigitte
Alric, Laurent
Armengol, Guillaume
Maillard, Hélène
Leguy-Seguin, Vanessa
Leroy, Sylvie
Rondeau-Lutz, Murielle
Lavigne, Christian
Mohamed, Shirine
Chaussavoine, Laurent
Magro, Pascal
Seguier, Julie
Kerjouan, Mallorie
Fourdrinoy, Sylvie https://orcid.org/0000-0003-0284-4234
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03695874 at ClinicalTrials.govDocuments that mention this clinical trial
Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
https://doi.org/10.1186/s13023-022-02426-2
-
Funding
Funding for this research was provided by:
AMRO HHT France (AAP 2017-2019)
- License Information
-
More Information
Article History
Received: 4 March 2022
Accepted: 30 June 2022
First Online: 19 July 2022
Declarations
:
: This research recorded on ClinicalTrials.gov (NCT03695874) was conducted in accordance with international ethical guidelines that are consistent with American Psychological Association norms and was approved by the local research ethics committee (Comité de Protection des Personnes CPP Sud-Est III: n°2018-A02128-47).
: Not applicable.
: The authors declare that they have no competing interests.
